Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Invested Capital (2019 - 2023)

Historic Return on Invested Capital for Lineage Cell Therapeutics (LCTX) over the last 6 years, with Q4 2023 value amounting to 0.35%.

  • Lineage Cell Therapeutics' Return on Invested Capital fell 2200.0% to 0.35% in Q4 2023 from the same period last year, while for Dec 2023 it was 0.35%, marking a year-over-year decrease of 2200.0%. This contributed to the annual value of 0.33% for FY2023, which is 600.0% down from last year.
  • As of Q4 2023, Lineage Cell Therapeutics' Return on Invested Capital stood at 0.35%, which was down 2200.0% from 0.34% recorded in Q3 2023.
  • Lineage Cell Therapeutics' Return on Invested Capital's 5-year high stood at 0.02% during Q3 2021, with a 5-year trough of 0.4% in Q3 2022.
  • Moreover, its 4-year median value for Return on Invested Capital was 0.32% (2023), whereas its average is 0.27%.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Return on Invested Capital tumbled by -3700bps in 2022 and then skyrocketed by 600bps in 2023.
  • Quarter analysis of 4 years shows Lineage Cell Therapeutics' Return on Invested Capital stood at 0.21% in 2019, then surged by 89bps to 0.02% in 2021, then crashed by -480bps to 0.13% in 2022, then tumbled by -168bps to 0.35% in 2023.
  • Its Return on Invested Capital was 0.35% in Q4 2023, compared to 0.34% in Q3 2023 and 0.32% in Q2 2023.